Medicenna Therapeutics Reports Strong Clinical Progress and Financial Stability in Q1 Fiscal 2026

Medicenna Therapeutics Corp ( (TSE:MDNA) ) just unveiled an update.

Medicenna Therapeutics Corp reported its first-quarter fiscal 2026 financial results and operational highlights, showcasing promising clinical outcomes from its MDNA11 and MDNA113 programs. The company remains on track to complete enrollment in its Phase 1/2 ABILITY-1 trial and anticipates key data readouts in the second half of 2025. Recent patent grants have strengthened its intellectual property portfolio, supporting its long-term commercial potential. With a cash runway extending into mid-2026, Medicenna is well-positioned to advance its clinical and preclinical programs, including its phase-3 ready glioblastoma program, bizaxofusp.

The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.

Spark’s Take on TSE:MDNA Stock

According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.

Medicenna Therapeutics Corp. receives a moderate overall score, reflecting its financial challenges and reliance on financing. However, positive results from clinical trials and promising preclinical data provide notable upside potential. Technical indicators are neutral, offering a balanced view of near-term stock performance. Valuation highlights the speculative nature typical of biotech stocks, while recent corporate events significantly bolster future growth prospects.

To see Spark’s full report on TSE:MDNA stock, click here.

More about Medicenna Therapeutics Corp

Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on developing Superkines targeting cancer, autoimmune, and inflammatory diseases. The company is engaged in advancing its IL-2 and IL-4 Superkine platforms, with a market focus on addressing unmet needs in patients who do not respond to existing blockbuster immunotherapies.

Average Trading Volume: 29,101

Technical Sentiment Signal: Sell

Current Market Cap: C$57.71M

For detailed information about MDNA stock, go to TipRanks’ Stock Analysis page.